

RESEARCH ARTICLE

Editorial Process: Submission:10/15/2018 Acceptance:08/26/2019

Role of CD135/CD117 on Prognosis and Overall Survival of Acute Myeloid Leukemia**Mortaza Raeisi¹, Ali Reza Nikhanfar², Babak Nejate², Ali Akabr Movassaghpoour Akbari², Roya Dolatkhah², Yousef Roosta², Zohreh Sanaat^{2*}****Abstract**

Background: The key proliferative RTKs for AML include c-KIT receptor (*CD117*) and FLT-3 receptor (*CD135*). The aim of this study was to evaluate the *CD135* and *CD117* expression, co-expression of *CD135* and *CD117* (*CD135+CD117*), and the association of that co-expression with Event Free Survival (DFS) and Overall Survival (OS) rates. **Material and Methods:** We analyzed *CD117* and *CD135* expression on AML blasts by flow cytometry and its association with Event Free Survival (DFS) and Overall Survival (OS) in 66 AML treated on Hematology-Oncology Research Center, Iran, Tabriz. **Results:** The overall OS and EFS were 50% and 80.3% respectively during our study. Cox-regression analysis revealed that a poor EFS was significantly associated a low *CD135* (HR 0.34, 95% CI 0.13–0.88, $P = 0.02$). **Conclusion:** This is the first study from Iran to show that the expressions of *CD135*, *CD117* is easily measurable by routine diagnostic flow-cytometry, and *CD135+117* were not significantly associated with CR, EFS, or OS .

Keywords: Acute myeloid leukemia- *CD135*- *CD117*- flow-cytometry*Asian Pac J Cancer Prev*, **20 (9)**, 2625-2631**Introduction**

Mutations in multiple genes and improper expressions by epigenetic abnormalities are common findings in most malignancies. A multi-stage mutation process has been posited in cancer research, with evidence of a combination of uncontrolled growth (oncogenes) and dysregulation of growth inhibition (tumor suppressor genes) (Kinzler and Vogelstein, 1997; Malaise et al., 2009). The tyrosine kinase receptors (RTKs) are a family of proteins that have a transmembrane domain and a tyrosine kinase motif (Muller-Tidow et al., 2004; Robinson et al., 2000). These act in cell signaling for the control of growth, differentiation, adhesion, migration, and apoptosis (Hubbard and Till, 2000; Muller-Tidow et al., 2004). Together with downstream effectors, RTKs are known to be key elements in the molecular pathogenesis of malignancy (Malaise et al., 2009). Specifically, mutations in RTKs have been identified in disorders such as myelodysplastic syndrome and acute myeloid leukemia (AML) (Malaise et al., 2009). Among these, AML is the most common leukemia in adults and continues to have the lowest survival rate of all leukemias (Carow et al., 1996; Linnekin, 1999; Sharawat et al., 2015). It is a heterogeneous clonal disease of haemopoietic progenitor cells (“blasts”) that lose the ability to differentiate and

proliferate (Malaise et al., 2009). Moreover, AML accounts for 1.1% of all new cancer cases in the USA, has a incidence of 4.3 per 100,000 men and women per year, and accounts for 2.8 deaths per 100,000 men and women per year. The disease is most frequently diagnosed among people aged 65–74 years (“Cancer Stat Facts: Leukemia - Acute Myeloid Leukemia (AML);”) (“Cancer Stat Facts: Leukemia - Acute Myeloid Leukemia (AML);”).

The pathogenesis of AML involves an imbalance between proliferation and apoptosis. RTKs contribute significantly to leukemogenesis, (Sharawat et al., 2013) with the stem cell factor receptor (c-Kit or *CD117*) and FMS-like kinase-3 (FLT3 or *CD135*) being key proliferative RTKs in AML (Sharawat et al., 2013). Both *CD117* and *CD135* are members of the class III RTK family and share the common structure of five extracellular immunoglobulin-like domains, a single transmembrane segment, a juxtamembrane domain, and a split cytoplasmic domain (Masson and Ronnstrand, 2009; Noronha et al., 2016). *CD117* is a 145-kD tyrosine kinase transmembrane receptor that is expressed in 4% of normal bone marrow mononuclear cells, including stem cells, progenitor cells, and mast cells (Ashman,et al., 1991; Wells et al., 1996). It is also a diagnostic marker of AML that is expressed in 85% of affected patients, (Bene et al.,

¹Tabriz University of Medical Sciences, ²Hematology and Oncology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. *For Correspondence: zohrehsanaat@yahoo.com

1998; Sharawat et al., 2013) and reports are unclear as to whether overexpression is related to outcomes (Ashman et al., 1988; Reuss-Borst et al., 1994; Sharawat et al., 2013). In addition, *CD135* overexpression is associated with poor results in AML (Graf et al., 2004). Given that both *CD117* and *CD135* are proliferative markers, increased expression of the markers indicates an increased proliferation index, which is known to be important to the pathophysiology of AML (Sharawat et al., 2013). To date, however, no data have been reported on the combined expression of both these proliferative markers, and there has been no evaluation of how they are related to the outcomes of AML.

The aim of this study was to evaluate the frequencies of *CD135* and *CD117* expressions in leukemic blast cells, the degree of *CD135* and *CD117* co-expression (*CD135+CD117*), and the association of that co-expression with the event-free survival (EFS) and overall survival (OS) rates.

Materials and Methods

Patient selection, treatment, and sampling

We enrolled consecutive patients with newly diagnosed de novo AML between September 2016 and December 2017 from the Hematology-Oncology Research Center, Iran, Tabriz. The study protocol was approved by the ethics committee of Tabriz University of Medical Sciences (Permit no 5/d/85187) and informed consent was obtained from participants to evaluate peripheral blood and/or bone marrow samples for the study. Patients with acute promyelocytic leukemia and acute lymphoblastic leukemia (ALL) were excluded.

Diagnosis and treatment

All diagnoses were made by the following techniques: (1) standard morphology and cytochemistry of peripheral blood and bone marrow films according to the French-American-British criteria (Newell et al., 2003) (before morphologic evaluation, staining was done with Wright's stain and hematoxylin and eosin); and (2) immunophenotyping with a comprehensive panel of monoclonal antibodies against myeloid- and lymphoid-associated antigens, as proposed by the European Group for the Immunological Characterization of Leukemias (Bene et al., 1998; Li et al., 2008; Malaise et al., 2009).

A uniform treatment protocol was followed for all patients. This involved induction with a 3+7 regimen (daunorubicin 45 mg/m² and cytosine arabinoside 100 mg/m²) followed by two cycles of a 5+2 protocol after remission (daunorubicin 45 mg/m² for 2 days, plus cytosine arabinoside 100 mg/m² for another 5 days). Patients who were not in complete remission (CR) morphologically after the first session of induction chemotherapy received cytosine arabinoside 500 mg/m² by slow intravenous push twice a day for 7 days and Novantrone 12 mg/m² daily for 3 days.

Flowcytometry

We obtained 5 mL of peripheral blood (if peripheral blots $\geq 30\%$) and bone marrow samples from patients and

stored them in anticoagulant ethylenediaminetetraacetic acid (EDTA) tubes until immunophenotyping was performed. The cell counts were done using a cytochemistry technique in an H1 autoanalyzer (Technicon, USA), and the number of leukocytes was adjusted to 5,000–10,000 cell isoton per microliter. Samples were stained directly using monoclonal tagged antibodies with fluorescence materials. Antibodies against human *CD135-PE*, *CD117-FITC* (BioLegend, USA), and white blood cells (WBCs) were gated and evaluated using the CD45-FITC index (Agilent DAKO, USA). In total, 5,000 events were acquired and the percent expressions of *CD135* and *CD117* on gated myeloblasts were recorded (Figure 1). The results were analyzed using the ProCell Quest software (BD, USA), and a threshold of 20% was taken to indicate cases positive for *CD117* and *CD135* expression Figure 1.

Clinical outcome assessment

After CR, all patients were examined every month for the first year and every 12 months thereafter. The OS and the EFS were the outcomes of interest: OS was defined as the time from diagnosis of AML to death from leukemia and/or the last follow-up time (December 2017); and EFS was defined as the time to the first event (remission, relapse, or death).

Statistical analysis

The baseline characteristics of patients were tested for normality using a test of skewness, and data were subsequently presented as mean (\pm SD) or as number and frequency, depending on the results. For categorization of quantitative values (including the expressions of *CD117*, *CD135*, and *CD135+CD117*), median values were calculated and used as cut-off points for categorized as high or low expression. We used the following cut-off points for other values: hemoglobin, <8 and ≥ 8 g/dL; WBC, $<30,000$ and $\geq 30,000$ /mm³; and platelets, $<30,000$ and $\geq 30,000$ /mm³.

The associations of *CD117* expression, *CD135* expression, and *CD135+CD117* co-expression with other values were evaluated by Kruskal-Wallis tests and t-tests, using their mean values. For the survival analyses, we performed log-rank tests by the Kaplan-Meier method to assess the independent prognostic effects of *CD117*, *CD135*, and *CD135+CD117* expressions in patients with AML. We also performed Cox-proportional regression analyses to obtain the hazard ratios (HRs), standard errors, and 95% confidence intervals (CIs) of the prognostic factors. The prognostic index for each patient was calculated as the hazard coefficient of the three main values (hemoglobin, WBC, and *CD135+117*) multiplied by their scores. Log-rank tests and the Kaplan-Meier method were used to evaluate the significance of means of prognostic indexes on the OS and EFS. P-values ≤ 0.05 were considered statistically significant. All statistical analyses were done using STATA 11.0.

Results

Patient characteristics

We enrolled 66 patients with AML in this study, among

Table 1. Baseline Patient Characteristics

Variable	Positive	Median expression
CD135	51 (77.3%)	72.5
CD117	56 (84.8%)	64.5
CD135+CD117	45 (68.2%)	46.5

whom 42 (63.6%) were male and 24 (36.4%) were female and the mean age was 45.55 ± 12.21 years (range, 18–60 years). The baseline characteristics are shown in Table 1.

Associations of patient characteristics with CD135 and CD117 expressions

CD135, CD117, and CD135+CD117 expressions on myoblasts were positive in 77.3%, 84.8%, and 68.2% of patients with AML, respectively; the corresponding median expressions were 72.5, 64.5, and 46.5, respectively (Table 2). There was a significant relationship between CD135 expression and a higher mean WBC count (73.3% versus 47.9%, $P = 0.002$), but there were no significant relationships between other patient characteristics and the expressions of either CD135 or CD117 alone. The relationship between a lower mean hemoglobin and CD135+CD117 co-expression approached significance (48.8% versus 35.4%, $P = 0.08$) (Table 3), but there were no significant relationships between any other patient

Table 2. Expression of CD135, CD117, and CD135+CD117

Variables	Patients (N=66)
Median age in years (range)	45.55 (18 to 60)
Sex (male:female)	03:01
Median hemoglobin (g/dl) (range)	7.6 (3.4–14.1)
Median WBC (/mm ³) (range)	14,645 (500–414,000)
Median Platelets (/mm ³)	415,000 (6000–2,74,000)
FAB subtype	
M0	4(6.1%)
M1	11(16.7%)
M2	34(51.5%)
M4	17(25.8%)

characteristic and CD135+CD117 co-expression.

Survival analysis based on CD135 and CD117 expressions

The mean follow-up time for OS was 197.83 ± 155.37 days. The OS was 50% and the mean OS was 303.72 days (range, 244.30–363.13 days), with a median of 290 days (range, 188.11–391.90 days). The mean follow-up time for EFS was 175.45 ± 136.47 days. The EFS was 80.3% and the mean EFS was 360.02 days (range, 317.36–402.67 days) with a median of 50.37 days (range, 323.29–520.72




Figure 1. Flow Cytometric Based Coexpression of CD135+CD117




Figure 2. Kaplan-Meier EFS Curves for (A) CD117, (B) CD135, (C) Coexpression of CD135 and CD117, and Kaplan-Meier OS Curves for (D) CD117, (E) CD135, (F) Coexpression of CD135 and CD117

Table 3. Association of *CD135*/*CD117* Coexpression with Baseline Patient Characteristics

Variables	<i>CD135</i> (mean ±SD)	P	<i>CD117</i> (mean ±SD)	P	<i>CD135+CD117</i> (mean ±SD)	P
Sex		0.3		0.9		0.2
Male (42)	55.9 ± 36.6		56.3 ± 27.7		39.7 ± 31.4	
Female (24)	63.6 ± 30.2		55.9 ± 30.0		48.4 ± 31.6	
Hemoglobin (g/dl)		0.1		0.1		0.08
<8 (37)	64.5 ± 31.1		60.4 ± 25.9		48.8 ± 30.0	
≥8 (29)	51.2 ± 37.3		50.6 ± 30.8		35.4 ± 32.3	
WBC (/mm ³)		0.002		0.5		0.2
<30,000 (38)	47.9 ± 35.6		57.9 ± 30.8		39.1 ± 34.4	
≥30,000 (28)	73.3 ± 26.8		53.75 ± 25.0		48.0 ± 26.9	
Platelets (/mm ³)		0.6		0.1		0.3
<30,000 (25)	56.2 ± 35.8		62.3 ± 25.0		47.7 ± 33.2	
≥30,000 (41)	60.2 ± 33.8		52.4 ± 29.9		40.0 ± 30.0	

Table 4. Univariate Survival Analysis for the *CD135*, *CD117*, and *CD135+CD117* Coexpression a. Mean /Days

Variables	CR %	P	EFS ^a ± SE (CI)	P	OS ^a ± SE (CI)	P
<i>CD117</i> (%)	< 64.5	0.82	326.57 ± 26.25 (275.13- 378.01)	0.88	269.49 ± 31.62 (207.51- 331.48)	0.92
	≥64.5	0.13	356.25 ± 29.51 (298.41- 414.09)		303.68 ± 41.44 (222.47- 384.90)	
<i>CD135</i> (%)	<72.5	0.50	347.86 ± 37.21 (274.93- 420.78)	0.54	246.69 ± 43.98 (190.49- 362.88)	0.37
	≥72.5	0.15	365.23 ± 28.67 (309.03- 421.43)		309.82 ± 34.83 (241.54- 378.09)	
<i>CD135+CD117</i> (%)	<46.5	0.16	361.70 ± 32.40 (298.20- 425.21)	0.91	341.84 ± 45.60 (252.47- 431.22)	0.33
	≥46.5	0.11	353.08 ± 31.68 (290.99- 415.18)		263.01 ± 33.78 (196.81- 329.22)	

days). *CD117+CD135* co-expression did not have a significant effect on either the OS (log-rank, P = 0.71) or the EFS (log-rank, p = 0.45). The CR rate was 40.9% overall, and at the median follow-up time of 168 days (range, 3–580 days), the OS and EFS were 73.98% ± 6.26% (CI: 59.31%–84.04%) and 47.61% ± 6.23% (95%CI, 35.05%–59.13%), respectively.

The association between patient outcome and the expressions of *CD135* and *CD117*

In the univariate analyses, the expressions of *CD135*, *CD117*, and *CD135+CD117* were not significantly associated with the CR, EFS, or OS (Table 4). However, after adjustment for hemoglobin, WBC, *CD117*, *CD135*, and *CD117+CD135*, cox-regression analysis showed that a poor EFS was significantly associated with a high hemoglobin (HR 0.41, 95% CI 1.89–0.90, P = 0.027) and a low *CD135* (HR 0.34, 95% CI 0.13–0.88, P = 0.02).

Cox-regression analysis also revealed that a poor OS was significantly associated with a high hemoglobin (HR 0.41, 95% CI 0.18–0.93, P = 0.03) and a low *CD135* (HR 0.36, 95% CI 0.14–0.93, P = 0.03). There were no significant associations between the EFS or the OS and either the mean WBC, the expression of *CD117*, or the co-expression of *CD135+CD117* (Table 5).

Based on the calculated coefficients, the following formula was used to calculate a prognostic index for each patient: ($-0.81 \times$ hemoglobin score) + ($0.36 \times$ WBC score) + ($0.04 \times$ *CD135+CD117* score). The median range of this prognostic index was then calculated and used to assess the OS (P = 0.74) and EFS (P = 0.72) at four different prognostic indexes (0.5, 1.0, 1.5, and 2.0), as shown in Figures 2 and 3.




Figure 3. Difference in OS (A) and EFS (B) of the 4 Cohorts Based on Prognostic Index as Created by Hazard Coefficient of all the Significant Predictors for OS in Multivariable Analysis.

Table 5. Multivariable Analysis with Significant Baseline Characteristics (Cox Proportional-Hazards Regression model)

Variables	EFS						OS					
	Hazard Ration	standard error	P	95% Confidence interval		Hazard Ration	standard error	P	95% Confidence interval			
Hemoglobin (g/dl)	<8	-	-	-	-	-	-	-	-	-	-	-
	≥8	0.41	0.16	0.02	1.89	0.90	0.41	0.17	0.03	0.18	0.93	
WBC (/mm ³)	<30,000	1.76	0.68	0.14	0.82	3.77	1.68	0.63	0.17	0.80	3.54	
	≥30,000	-	-	-	-	-	-	-	-	-	-	-
CD117 (%)	<64.5	0.84	0.93	0.71	0.34	2.09	0.75	0.34	0.54	0.31	1.84	
	≥64.5	-	-	-	-	-	-	-	-	-	-	-
CD135 (%)	<72.5	0.34	0.16	0.02	0.13	0.88	0.36	0.17	0.03	0.14	0.93	
	≥72.5	-	-	-	-	-	-	-	-	-	-	-
CD135 + CD117 (%)	<46.5	1.68	0.81	0.27	0.65	4.32	1.95	0.96	0.17	0.74	5.14	
	≥46.5	-	-	-	-	-	-	-	-	-	-	-

Discussion

AML is the most common leukemia in adults, yet it continues to have the lowest survival rate (Carow et al., 1996; Linnekin, 1999; Sharawat et al., 2015). The key proliferative RTKs in AML are CD117 and CD135 (Sharawat et al., 2013) and whereas the role of CD117 remains uncertain in hematopoietic neoplasia, the CD135 antigen is recognized as the FLT3 ligand of its receptor-signaling pathway. Although it is rarely tested in acute leukemia (Noronha et al., 2016; Paietta et al., 2004) a few studies have found that the CD135 antigen is highly expressed in B-cell ALL, in B-cell lines, in AML, and to a lesser degree in T-cell ALL (Drexler, 1996; Noronha et al., 2016; Wells et al., 1996). In the present study, the expressions of CD135, CD117, and CD135+CD117 were explored in 66 patients with AML, and they were shown to be expressed on the myoblasts of 77.3%, 84.8%, and 68.2% of patients with AML, respectively (Table 2). This is consistent with research by Wells et al., (1996) where CD117 was present in 87% of cases of AML, and with the results of a cohort study by Sharawat et al., (2013), where CD135 and CD117 expressions >20% were observed in 82% and 90% of patients' myeloblasts. Tarlock et al., (2017) reported that there was no significant association between CD135 expression and the WBC count. In our study, however, there was a significant relationship between CD135 expression and a higher mean WBC count (73.3% versus 47.9%, P = 0.002), although we cannot exclude the possibility that this was caused by our small sample. We could find no associations between other patient characteristics and the expressions of CD135, CD117, or CD135+CD117. The co-expression of CD135+CD117 has been discussed by Wells et al., (1996) but there have been no reports of how they relate to the OS and EFS. The co-expression of CD135+CD117 did not significantly affect the OS (log-rank, P = 0.71) or the EFS (log-rank, p = 0.45) in our study. However, in a cohort study by Sharawat et al., (2013), univariate analysis indicated that high expression of CD135 and high co-expression of CD135+CD117 was significantly associated with the CR rate (P < 0.001 and

P < 0.006, respectively). We found no such relationship, which again was probably due to the small sample size. Multivariable analysis in the study by Sharawat et al., (2013). Also showed that the expressions of CD135 or CD117 alone did not predict survival, but it did show that their co-expression was the strongest independent predictor of both EFS (HR 2.46) and OS (HR 2.25). Our cox-regression analysis revealed that poor EFS and OS rates were significantly associated with high hemoglobin levels and low CD135 expression (Table 5).

This study represents the first in Iran to show a correlation between RTKs (CD135 and CD117) and poor survival in patients with AML. However, this study is not without limitations. We only analyzed a small number of cases and cannot exclude the possibility of selection bias. Also, the study had a short follow-up period for determining survival compared with other studies on this topic, making it difficult to assess the full impact of CD135+CD117 co-expression on disease progression and death. Despite these limitations, our study benefits from having evaluated the expressions of CD117, CD135, and CD135+CD117 in patients with AML in the context of the EFS and OS. This is important because clinical trials have used FLT3 antagonists therapeutically, and one of the most famous ones involved using c-KIT inhibitors in patients with elevated CD135 and CD117 expressions (Sharawat et al., 2013). This remains a promising area for future research and treatment.

In conclusion, in summary, we have shown that CD135 and CD117 co-expression was observed in 68.2% of patients with AML in our cohort in Iran. This expression is easily measured by conventional diagnostic flowcytometry techniques and could be used as an independent prognostic marker of AML. Considering the results of this study, a large study is needed to assess the efficacy of the identified markers included in our prognostic index (i.e., WBC count, hemoglobin level, and the percentage co-expression of CD135 and CD117).

Acknowledgments

The authors would like to thank the Hematology and

Oncology Research Center for supporting this research study (grant no 95/7). This study was conducted as part of a fellowship thesis for Dr Raeisi (thesis no 94/2-12/54). Dr Robert Sykes (www.doctored.org.uk) provided technical editing services for the final drafts of this manuscript.

Author contributions

MR provided substantial contributions to conception and design of manuscript, drafting the article, final approval of the version to be published, agreement to be accountable for all aspects of the work in ensuring that questions related to accuracy or integrity of any part of the work are appropriately investigated and resolved.

AN contributed to analysis and interpretation of results, revising the article critically for important intellectual content, final approval of the version to be published, agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

AE contributed to analysis and interpretation of results, revising the article critically for important intellectual content, final approval of the version to be published, agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

BN contributed to analysis and interpretation of results, revising the article critically for important intellectual content, final approval of the version to be published, agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

AAMA contributed to analysis and interpretation of flow cytometers results, revising the article critically for important intellectual content, final approval of the version to be published, agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

TR contributed to analysis and interpretation of results, revising the article critically for important intellectual content, final approval of the version to be published, agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

RD contributed to analysis and interpretation of results, revising the article critically for important intellectual content, final approval of the version to be published, agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

ZS provided substantial contributions to conception and design of manuscript, drafting the article, final approval of the version to be published, agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of

the work are appropriately investigated and resolved.

Disclosure

The authors report no conflicts of interest in this work.

References

- Ashman LK, Cambareri AC, To LB, Levinsky RJ, Juttner CA (1991). Expression of the YB5.B8 antigen (c-kit proto-oncogene product) in normal human bone marrow. *Blood*, **78**, 30-7.
- Ashman LK, Roberts MM, Gadd SJ, Cooper SJ, Juttner CA (1988). Expression of a 150-kD cell surface antigen identified by monoclonal antibody YB5.B8 is associated with poor prognosis in acute non-lymphoblastic leukaemia. *Leuk Res*, **12**, 923-8.
- Bene MC, Bernier M, Casasnovas RO, et al (1998). The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). *Blood*, **92**, 596-9.
- Cancer Stat Facts: Leukemia - Acute Myeloid Leukemia (AML). Retrieved 2018/22/8, from NIH, National Cancer Institute
- Carow CE, Levenstein M, Kaufmann, et al (1996). Expression of the hematopoietic growth factor receptor FLT3 (STK-1/ Flk2) in human leukemias. *Blood*, **87**, 1089-96.
- Drexler HG (1996). Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. *Leukemia*, **10**, 588-99.
- Graf M, Hecht K, Reif S, et al (2004). Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. *Eur J Haematol*, **72**, 89-106.
- Hubbard SR, Till JH (2000). Protein tyrosine kinase structure and function. *Annu Rev Biochem*, **69**, 373-98.
- Kinzler KW, Vogelstein B (1997). Cancer-susceptibility genes. Gatekeepers and caretakers. *Nature*, **386**, 761- 3.
- Li L, Piloto O, Nguyen HB, et al (2008). Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model. *Blood*, **111**, 3849-58.
- Linnekin D (1999). Early signaling pathways activated by c-Kit in hematopoietic cells. *Int J Biochem Cell Biol*, **31**, 1053-74.
- Malaise M, Steinbach D, Corbacioglu S (2009). Clinical implications of c-Kit mutations in acute myelogenous leukemia. *Curr Hematol Malig Rep*, **4**, 77-82.
- Masson K, Ronnstrand L (2009). Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. *Cell Signal*, **21**, 1717-26.
- Muller-Tidow C, Schwable J, Steffen B, et al (2004). High-throughput analysis of genome-wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. *Clin Cancer Res*, **10**, 1241-9.
- Newell JO, Cessna MH, Greenwood J, et al (2003). Importance of CD117 in the evaluation of acute leukemias by flow cytometry. *Cytometry B Clin Cytom*, **52**, 40-3.
- Noronha EP, Andrade FG, Zampier C, et al (2016). Immunophenotyping with CD135 and CD117 predicts the FLT3, IL-7R and TLX3 gene mutations in childhood T-cell acute leukemia. *Blood Cells Mol Dis*, **57**, 74-80.
- Paietta E, Ferrando AA, Neuberg D, et al (2004). Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. *Blood*, **104**, 558-60.
- Reuss-Borst MA, Buhring HJ, Schmidt H, Muller CA (1994). AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression. *Leukemia*, **8**, 258-63.
- Robinson DR, Wu YM, Lin SF (2000). The protein tyrosine kinase family of the human genome. *Oncogene*, **19**, 5548-57.

Sharawat SK, Bakhshi R, Vishnubhatla S, Bakhshi S (2015).

High receptor tyrosine kinase (FLT3, KIT) transcript versus anti-apoptotic (BCL2) transcript ratio independently predicts inferior outcome in pediatric acute myeloid leukemia. *Blood Cells Mol Dis*, **54**, 56-64.

Sharawat SK, Gupta R, Raina V, et al (2013). Increased coexpression of c-KIT and FLT3 receptors on myeloblasts: independent predictor of poor outcome in pediatric acute myeloid leukemia. *Cytometry B Clin Cytom*, **84**, 390-7.

Tarlock K, Alonzo TA, Loken MR, et al (2017). Disease characteristics and prognostic implications of cell-surface FLT3 receptor (CD135) expression in pediatric acute myeloid leukemia: A Report from the Children's Oncology Group. *Clin Cancer Res*, **23**, 3649-56.

Wells SJ, Bray RA, Stempora LL, Farhi DC (1996). CD117/CD34 expression in leukemic blasts. *Am J Clin Pathol*, **106**, 192-5.



This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License.